Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented as Platform Presentation

Aerosurf Utilizing Chrysalis Aerosol-Generator Technology Demonstrates Optimal Functional Activity

WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.

Phase 2 Clinical Trial of Surfaxin(r) for the Prevention and Treatment of BPD

Carl Bose, MD, Director of Neonatology and Professor of Pediatrics at University of North Carolina and Chairman of the Discovery BPD Clinical Study Steering Committee, presented an overview of key trial data. These data suggest that Surfaxin, when administered beyond the standard acute Respiratory Distress Syndrome (RDS) treatment period, may represent a novel therapeutic option for infants at risk for developing BPD. BPD is a chronic, debilitating lung disease affecting premature infants who survive treatment for RDS. Presently, there are no approved pharmaceutical therapies for BPD.

Surfaxin was shown to be generally safe and well-tolerated. Top-line results demonstrated that infants treated with up to five incremental standard doses of Surfaxin experienced:

* a lower incidence of death or BPD,

* a higher survival rate thr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ... for the fourth quarter of 2013 on Monday, February ... scheduled for release after the close of trading. ... will hold a conference call to discuss the operating ... twelve months ended December 31, 2013 on February 3, ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... maintain the anatomical reduction (spacing) of the scaphoid and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, ... development of disease modifying therapeutics for Alzheimer,s disease ... relocation of its corporate headquarters to ... 2014 and expanded lease agreement for additional laboratory ... Oligomerix, which is focused on the development of ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey ... is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the ... , , ... , , ...
... Calif. , July 22 SRI International and the ... Collaborative (the Multidisciplinary Initiative for Surgical Technology Research Advanced Laboratory), in ... $1M grant by the Food and Drug Administration (FDA) ... care. , , ...
Cached Medicine Technology:Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 2Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... marketer and,distributor of pharmaceutical, medicinal and diagnostic products ... conference call at 5:00 p.m. Eastern,Time on May ... financial results., Joining Mr. Yan-qing Liu, Chairman, ...
... baby was bottle-fed, researchers noted , , TUESDAY, May 13 ... than one year reduce their risk of rheumatoid arthritis ... , The researchers also found that having children but ... , Taking oral contraceptives also failed to reduce the ...
... -- Promising results from a team of NewYork-Presbyterian Hospital/Weill ... both safe and effective at slowing the progression of ... a rare, genetic, degenerative neurological disorder that usually becomes ... 12. , The clinical trial found that the ...
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... a,renegade internet radio broadcaster and production company promoter, but ... particularly those with,disabilities - not exactly what you,d expect ... with the Hard Rock Cafe at Station Square,Lawless and ... planned,Pittsburgh,s first annual Rock for Autism on June 11, ...
... A complete review of trends in,weight loss research ... to weight loss, according to Edward Zbella, M.D.,Medical ... proven,weight management strategies in combination with a personal, ... success., NBC,s hit show The Biggest Loser ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2Health News:Rockin' Out for Autism in Pittsburgh 2Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Medicine Products: